This year, we are concluding our 10-year survey on vein disease in children. It is evident meanwhile that varicose veins are based on congenital vein valve damage. We are going to learn which lesions will have fast progression, and which may last stable subclinical for decades. We will also report on a clinical study on the new method of hyaluronan-based vein valve repair.

Research on pressure-induced vein valve damage is proceeding. While general pressure increase by long-term sitting or standing which can partially counteracted by compression stockings, the progression of mechanical valve damage is not at all met by traditional compression. Thus, stockings may reduce discomfort and edema in late stages of insufficiency, but they do not contribute to causal early-stage prevention

Dr. Johann Christof Ragg, founder of the Angioclinic^® vein centers is a trailblazer in vascular research. Venartis^®, founded by Dr. Ragg, holds a portfolio of high impact expertise in the realm of minimally invasive and preventative vein therapies.

Why Invest in VENARTIS®?
The opportunities for investors in this field are substantial. We are addressing a widespread, global health concern with life-changing technologies. As pioneers in minimally invasive techniques and preventive care, we are setting new benchmarks for the entire industry. With over 25 years of groundbreaking research and a trove of international patents we are unrivaled leaders in vein care solutions. Use the contact form below for access to in-depth information.